Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status approved; investigational
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 0781-9253; 14096-121; 81955-0012; 16729-306; 55150-393; 63323-771; 68001-527; 69097-368; 69097-805; 71288-153; 72485-201; 65129-1222; 68554-0104; 72606-558; 53183-4011; 43598-678; 59572-102; 51916-350; 83137-0006; 16714-927; 43817-906; 59572-730; 68001-504; 71288-115; 63660-0010; 0781-3253; 42385-312; 66529-0013; 54893-0029; 82920-015; 68001-313; 42385-719; 43598-305; 16714-578; 51991-797; 64679-096; 70121-1237; 63592-1800; 0143-9606; 43598-143; 43598-465; 59572-740
UNII M801H13NRU
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vomiting07.01.07.0030.008395%
Weight decreased13.15.01.005--
Wheezing22.03.01.009--
Musculoskeletal disorder15.03.05.0250.000392%Not Available
Hypoacusis04.02.01.0060.000336%
Peripheral swelling02.05.04.015; 08.01.03.053--Not Available
Weight fluctuation14.03.02.0020.000112%Not Available
Neutropenic sepsis11.01.11.006; 01.02.03.007--Not Available
General physical health deterioration08.01.03.0180.003638%Not Available
Anal haemorrhage24.07.02.029; 07.12.03.0040.000168%
Upper respiratory tract inflammation22.12.03.0340.000224%Not Available
Left ventricular dysfunction02.04.02.0110.000168%
Shock haemorrhagic14.05.05.003; 24.06.02.0140.000168%Not Available
Cardiac death08.04.01.007; 02.03.04.015--Not Available
Intervertebral disc protrusion15.10.01.0040.000112%Not Available
Subileus07.13.01.0040.000224%Not Available
Abscess limb15.03.05.001; 11.01.08.014--Not Available
Contusion15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001--
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Lower gastrointestinal haemorrhage07.12.03.011; 24.07.02.0300.000336%
Staphylococcal bacteraemia11.02.05.001--Not Available
Post procedural haemorrhage24.07.01.014; 12.02.05.004--
Lacunar infarction24.04.06.009; 17.08.01.0160.000112%Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000336%Not Available
Catheter site haemorrhage24.07.01.003; 12.07.02.002; 08.02.02.002--Not Available
Systemic inflammatory response syndrome10.02.01.008; 08.01.05.005; 24.06.03.0080.000168%Not Available
Malignant neoplasm progression16.16.01.005--Not Available
Injection site discolouration23.03.03.046; 12.07.03.038; 08.02.03.038--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000280%Not Available
Skin induration23.03.03.020--
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 19 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene